Hypertension guidelines: effect of blood pressure targets by Touyz, Rhian M.
  
 
 
Touyz, R. M. (2019) Hypertension guidelines: effect of blood pressure targets. Canadian 
Journal of Cardiology, 35(5), pp. 564-569.  
(doi:10.1016/j.cjca.2019.03.014) 
 
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/193239/ 
      
 
 
 
 
 
 
Deposited on: 20 January 2020 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
 
Hypertension guidelines: impact of blood pressure targets  
 
Rhian M Touyz MD, PhD 
Institute of Cardiovascular and Medical Sciences, University of Glasgow;UK 
 
 
 
 
 
 
Short title: Impact of hypertension guidelines  
 
Keywords: blood pressure, targets, thresholds, cardiovascular risk, risk, harm, benefit 
 
 
 
Correspondence  
Rhian M Touyz MD, PhD 
Institute of Cardiovascular and Medical Sciences, 
University of Glasgow, 
126 University Place, Glasgow, G12 8TA, 
Phone: + 44 (0)141 330 7775/7774, Fax: + 44 (0)141 330 3360, 
Email: Rhian.Touyz@glasgow.ac.uk 
 2 
 
Abstract 
There has been an abundance of hypertension guidelines in recent years. The purpose of these is to 
convey evidence-based findings from clinical trials to clinicians so that best medical choices can be 
made for the diagnosis and treatment of patients with hypertension. Over the past 3 years new 
hypertension guidelines have been published in the United States, Canada, Europe and elsewhere with 
new or refined recommendations made regarding diagnosis, therapy and intensity of treatment. 
Previous national guidelines were generally in alignment with each other. However, there are major 
differences in the current North American and European recommendations in terms of the 
classification of hypertension and treatment goals, with diagnosis of hypertension starting at 140/90 
mmHg for the European guidelines and 130/80 mmHg for the United States and Canadian guidelines. 
An important controversial aspect in the updated guidelines relates to the lowered threshold (130/80 
mmHg) at which hypertension is diagnosed and treated, because growing evidence indicates that those 
at low cardiovascular risk may be exposed to incremental harm due to overtreatment with 
antihypertensive drugs. However these concerns need to be weighed against the robust evidence from 
the landmark SPRINT study and numerous meta-analyses that clearly showed that intensive blood 
pressure lowering aimed at systolic blood pressure of 120-130 mmHg causes ̴a significant reduction 
of over 25%  in cardiovascular morbidity and mortality. This review highlights some of the important 
discrepancies between the major current guidelines focusing on definitions and treatment goals of 
hypertension. The impact of lower blood pressure targets and intensive antihypertensive treatment on 
cardiovascular benefit and risk is discussed.    
Summary  
Updated American and Canadian hypertension guidelines have redefined hypertension (130/80 
mmHg) and treatment goals and advocate tighter blood pressure control at lower targets than 
previous guidelines. European guidelines are more conservative and maintain traditional definitions 
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of blood pressure (>140/90 mmHg). This review discusses the benefits and risks of stricter blood 
pressure control and the impact of different guidelines on the hypertension burden. 
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Introduction 
Hypertension is the leading modifiable risk factor for disability and premature death from 
cardiovascular disease and accounts for  10% of health care spending globally (1,2).  Accordingly 
blood pressure reduction should be a priority in every health care system. Considering the availability 
of a wide range of effective antihypertensive drugs that are well tolerated and generally affordable, it 
is surprising that in our modern society hypertension is so poorly controlled, with recent data indicating 
that in treated patients only  30% achieve adequate blood pressure control (2-4). Chobanian, in his 
Shattuck lecture described this as the ‘hypertension paradox’ where there is more uncontrolled disease 
despite improved therapy (5). Reasons for this are complex and multifactorial including poor 
adherence and compliance of drug treatment, therapeutic inertia, sub-optimal therapy and inadequate 
dosing (4,5). Further complicating these matters is the lack of clarity regarding optimal blood pressure 
targets, especially in hypertensive patients with co-morbidities, such as diabetes and kidney diseases 
and in the very elderly (2,6). The actual blood pressure thresholds at which treatment should be 
commenced and the target levels at which blood pressure should be maintained are a subject of intense 
discussion (7). To help address this, guidelines have been developed by experts to guide clinicians in 
the diagnosis and management of hypertension.  
Most major hypertension guidelines are evidence-based and are usually dictated by randomized 
controlled trial data and observational clinical studies (8). Recommendations are made to enable busy 
practitioners to follow best practice, establish best standards of care and provide appropriate and 
balanced treatment to patients. Guidelines are usually written by experts in the field who scrutinize 
relevant published clinical studies and trials, resulting in evidence-based recommendations. However, 
despite the apparent rigor, not all guidelines are the same and this is most evident when comparing the 
2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines (9) with 
the current European hypertension guidelines (10). Main differences relate especially to definition of 
hypertension and  blood pressure treatment targets.  
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Until fairly recently hypertension was generally diagnosed as a sustained office blood pressure 
greater than 140/90 mmHg, with clinical guidelines suggesting commencement of pharmacologic 
treatment when blood pressure is above this level. However in  2017 the ACC/AHA reclassified 
hypertension by lowering the threshold for treatment from 140/90 mmHg to 130/80 mmHg (9). 
Moreover these guidelines recommended that pharmacologic treatment should be initiated in patients 
with a blood pressure >130/80 mmHg and who are at high risk, defined as individuals with existing 
cardiovascular disease, a calculated 10-year cardiovascular risk of > 10% or those who have other risk 
factors (eg kidney disease or diabetes). In all patients with a blood pressure of > 140/90 mmHg 
independent of risk factors, ACC/AHA guidelines suggest that treatment should be initiated. Similar 
recommendations were soon adopted by many other major national guidelines including the Canadian 
Hypertension Education Program (CHEP) (11) and the International Society of 
Hypertension/American Society of Hypertension (12). The evidence underpinning the lower blood 
pressure targets was driven in large part by the Systolic Blood Pressure Intervention Trial (SPRINT), 
which demonstrated that intensive treatment to lower blood pressure targets is cardiovascular 
protective (13). Various meta-analyses also showed benefit of intensive blood pressure lowering. In a 
meta-analysis of over 44,000 patients, intensive blood pressure lowering below 140 mmHg was 
associated with improved cardiovascular and renal outcomes (14). In another study of over 613,000 
participants lowering blood pressure to a systolic blood pressure of less than 130 mmHg was associated 
with significantly reduced cardiovascular events and mortality (15).  
Systolic Blood Pressure Intervention Trial (SPRINT) 
The SPRINT study was a ground breaking trial that investigated effects of intensive blood pressure 
therapy on risk of cardiovascular disease and events in patients with hypertension (13). The primary 
outcome was a composite of heart failure, acute coronary syndrome, myocardial infarction and stroke. 
The trial enrolled 9,361 patients. Patients at least 50 years of age with at least one cardiovascular risk 
factor were randomly assigned to intensive treatment with a systolic blood pressure goal of <120 
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mmHg or standard treatment with a systolic blood pressure goal of <140 mmHg. The 5 year trial was 
terminated prematurely after 3.26 years because the primary composite outcome in the intensive 
treatment group showed a significant reduction, with a  25% relative risk reduction versus standard 
therapy. These findings underscored the implementation of intensive treatment of blood pressure to 
lower targets in the ACC/AHA and CHEP guidelines. It has been estimated that implementing such 
approaches could prevent 107,500 premature deaths from cardiovascular death annually (16).  
Hypertension guidelines in North America and Europe  
Following the 2017 ACC/AHA recommendations, the 2018 European Society of Cardiology and the 
European Society of Hypertension (ESC/ESH) guidelines on the diagnosis and management of 
hypertension were published (10). While both reports were developed using similar evidence-based 
clinical data, the recommendations differ with respect to two main points, 1) the classification of 
hypertension and 2) treatment goals. The ACC/AHA guidelines in the USA (9) and the CHEP 
guidelines in Canada (10) lowered the threshold for hypertension to 130/80 mmHg, while guidelines 
in Europe, UK and other regions such as Australia (16-18) have largely maintained traditional blood 
pressure categories, with grade 1 hypertension defined as an office blood pressure >140/90 mmHg. 
The ESC/ESH also introduced the concept of ‘safety boundaries’, defined as treated systolic blood 
pressure not below 130 mmHg in people >65 years and not below 120 mmHg in people <65 years. 
This cautious strategy is based on concerns of potential adverse events associated with overtreatment 
with antihypertensive drugs and is supported by the findings of Bress et al (19) who reported that over 
a 10 year period the number of cardiovascular events that would be prevented by intense blood pressure 
management would be similar to the number of serious adverse events. In response to these concerns, 
the American College of Physicians and the American Academy of Family Physicians (ACP/AAFP) 
developed their own guidelines for hypertension management in the USA for adults older than 60 
years, suggesting a blood pressure target of 150 mmHg at which level treatment should be started (20). 
Similar to the ESC/ESH guidelines and ACP/AAFP guidelines,  the 2019 National Institute for Health 
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and Clinical Excellence (NICE) guidelines also maintained  a conservative approach (21). Current 
recommendations of NICE  have not changed the definition of hypertension of 140/90 mmHg from 
the previous 201 iteration (17).  
The impact of lower diagnostic thresholds on the global hypertension burden.  
Redefining hypertension from 140/90 mmHg to 130/80 mmHg classifies previously 
‘normotensive/prehypertensive’ individuals as being ‘hypertensive’ who may require treatment.  The 
impact of this on the hypertension burden nationally and globally is enormous, both in terms of the 
prevalence of hypertension and the number of individuals requiring healthcare and antihypertensive 
therapy (22). By applying the new definitions, the prevalence of hypertension in adults younger than 
45 years triples for men and doubles for women in the Unites States (23). Numerous large studies 
further confirmed this in the general adult population. The Reasons for Geographic And Racial 
Differences in Stroke (REGARDS) study reported that adopting the 2107ACC/AHA definitions would 
double the prevalence of hypertension worldwide (24).  Similar findings were demonstrated in the US 
National Health and Nutrition Examination Survey (NHANES) and the China Health and Retirement 
Longitudinal Study (CHARLS) (25). Based on diagnostic criteria of 140/90 mmHg, the global 
prevalence of hypertension in adults is currently 30-35%. However applying the 2017 ACC/AHA or 
CHEP guidelines, increases the global prevalence of hypertension in adults to > 60%. Associated with 
this, the number of patients requiring treatment would be doubled and those already on treatment 
would require intensification of pharmacotherapy. Hence the potential impact of the hypertension 
burden on healthcare systems is significant.  
Another important consideration with the lower threshold for diagnosing hypertension using 
the ACC/AHA or CHEP criteria, is at the individual patient level,  where people will be labeled as 
being hypertensive and unwell, even though they may be at low risk of disease (26,27). This may 
impact adversely on their sense of well-being and could have negative implications on personal health 
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insurance and other situations (eg jobs) if they are considered to have a preexisting medical condition 
(28).  
Impact of guidelines on benefits and risks- effects of intensive treatment 
Collaborative meta-analysis of individual participant data from separate prospective studies clearly 
indicates that the relative risk of mortality due to cardiovascular disease in adults doubles with every 
20 mmHg increase in systolic blood pressure or 10 mmHg increase in diastolic blood pressure (29). 
This positive relationship holds true for systolic blood pressures from as low as 115 mmHg, below 
which there is little evidence. In adults 40-69 years, each difference of 20 mmHg systolic blood 
pressure is associated with more than a twofold difference in the rate of death due to stroke, ischaemic 
heart disease and other vascular causes (29). Hence aggressive efforts at reducing blood pressure 
should be a priority to ensure good cardiovascular health and prevention of premature death due to 
cardiovascular disease. However, the level of blood pressure at which such treatment efforts should be 
initiated is currently a matter of deliberation (7,30). 
It is predicted that implementing, achieving and maintaining the ACC/AHA guideline goals 
could prevent 3.0 million cardiovascular disease events over 10 years compared with the number of 
events prevented using prior guidelines (19). However, these benefits may be associated with potential 
risks, especially related to serious adverse events of overtreatment with antihypertensive drugs. The 
forecast is that implementation of the 2017 ACC/AHA guidelines would not only prevent 
cardiovascular events but would also lead to about 3 million more treatment-related serious adverse 
events (19).  
Concerns have also been raised regarding the ACC/AHA recommendations in patients with 
mild hypertension and low cardiovascular risk and questions are being raised as to whether these 
individuals should be treated with antihypertensive drugs since since there is a lack of supporting 
clinical evidence (31,32).  This was recently addressed in a longitudinal cohort study using electronic 
health records from 38 286 low risk patients with mild hypertension. Data were extracted from the 
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Clinical Practice Research Datalink (33). The study failed to show an association between exposure to 
antihypertensive treatment and mortality or cardiovascular disease. On the other hand, there was 
evidence that treatment may be associated with an increased risk of adverse events including 
hypotension, syncope and acute kidney disease. Hence antihypertensive treatment in low risk patients 
with mild hypertension may have little benefit and may actually be associated with some harm (27,31).  
Taken together these recent provocative studies emphasize the importance of weighing benefit 
versus risk and harm in treating patients aggressively to lower blood pressure targets, especially in 
those who have no or few risk factors. Guidelines simply provide recommendations and that clinical 
judgement and the need to individualize antihypertensive treatment taking into account comorbidities 
and associated cardiovascular risk factors, should remain the basis of hypertension management. 
Impact of lower blood pressure targets on dementia and chronic kidney disease.  
i) Dementia and cognitive impairment.  
A potential risk and clinical concern of overtreatment of hypertension is hypotension and cerebral 
hypoperfusion with consequent negative impact on the brain and cognition. The recent SPRINT MIND 
study, a substudy of SPRINT, specifically questioned whether intensive blood pressure control reduces 
the occurrence of dementia (34).  Results showed that unlike beneficial effects on cardiovascular 
events, intensive BP aimed at < 120 mmHg compared with <140 mmHg did not significantly decrease 
the incidence of probable dementia. However intensive blood pressure control was associated with a 
significant reduction in mild cognitive impairment, a risk factor for dementia. It should be highlighted 
that although dementia rates were not altered in SPRINT MIND, there was no evidence of cerebral 
hypoperfusion and no harm to cognition in patients treated to lower blood pressure levels.  SPRINT 
was terminated early because of significant cardiovascular benefit, and accordingly the trial may have 
been underpowered to evaluate the primary adjudicated cognitive outcome of probable dementia. 
Perhaps had the trial extended beyond the 3.26 years, significance on probable dementia rates may 
have been evident. Whether the outcomes would be beneficial or harmful is unknown, but hopefully 
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SPRINT patients will be followed long term to gain better insights into dementia outcomes over time 
in this patient cohort. Although lower blood pressure was not associated with cognitive harm in 
SPRINT, it should be emphasized that the trial did not focus on mean arterial pressure and pulse 
pressure, which are primary drivers of cerebral blood flow (35).  
ii). Chronic kidney disease.  
Hypertension and chronic kidney disease are common comorbidities, with high mortality risk. Blood 
pressure lowering is associated with reduced cardiovascular events in these patients (36). However 
there is still deliberation about the optimal blood pressure and therapeutic goal. Guidelines differ on 
blood pressure targets with the 2017 ACC/AHA recommending a goal of <130/80 mmHg in patients 
with chronic kidney disease while the European guidelines favor a higher systolic blood pressure goal 
of 130-140 mmHg. Numerous trials have examined effects of intensive blood pressure control on 
cardiovascular events and all-cause mortality in patients with hypertension and chronic kidney disease. 
Data from large meta-analyses have not been consistent with some studies showing benefit only in 
patients with  proteinuria (36) and others reporting clear benefit of more intensive blood pressure 
control in patients with stage 3-5 chronic kidney disease (37). Some studies have reported worsening 
of renal disease with tighter blood pressure control, especially in patients with diabetes (38-40). In a 
case control study, incident chronic kidney disease in the setting of intensive systolic blood pressure 
lowering was accompanied by decreases, rather than elevations, in levels of kidney damage 
biomarkers (41). A recent meta-analysis comprising four major trials (Modification of Diet in Renal 
Disease (MDRD); African American Study of Kidney Disease and Hypertension (AASK); Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) and SPRINT) compared intensive versus 
standard blood pressure approaches. Results clearly showed that intensive blood pressure management 
improves survival of patients with hypertension and chronic kidney disease, supporting the lower 
targets suggested by some current guidelines (42). Nevertheless, within the context of high risk patients 
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with chronic kidney disease, treatment of hypertension should be adapted to each individual patient, 
taking into consideration associated risk factors. 
Conclusions 
Hypertension guidelines all have the same overall objective of communicating evidence-based data 
from clinical trials to practitioners providing recommendations for best clinical practice and best care 
for patients with hypertension. Despite the plethora of international, national and regional guidelines, 
the prevalence of hypertension is high and control rates remain disappointingly low worldwide, due to 
many complex factors. This is likely to worsen with changing definitions of hypertension and lower 
blood pressure targets for treatment.  The updated recommendations in Europe and the UK, together 
with the guidelines of the ACP/AAFP are in general alignment that treatment of patients should aim 
at lowering blood pressure to 140/90 mmHg (43).  However these guidelines are at odds with the 
current ACC/AHA and CHEP guidelines, which have lowered the threshold to 130/80 mmHg. These 
disparities in the recommendations likely reflect a lack of consistent evidence from clinical trials and 
studies. The more conservative approach of the EU and NICE guidelines is based in large part on the 
potential risks and harm associated with intensive antihypertensive treatment to lower BP targets while 
the ACC/AHA guidelines are driven by the proven benefit of intensive treatment shown by SPRINT, 
which unambiguously showed a 25% reduction of morbidity and death associated with cardiovascular 
disease, despite some risk of adverse events. Such discrepancies add confusion and challenges to 
diagnostic and treatment choices for the busy clinician managing patients with hypertension. From a 
pragmatic viewpoint, it should be underscored that guidelines are merely recommendations based on 
the best available evidence aimed at guiding decisions and criteria regarding diagnosis and that the 
central element in decision-making for our hypertensive patients depends on good clinical judgment. 
Moreover, clinicians should strongly advocate and actively prescribe healthy lifestyle choices for all 
hypertensive patients independently of whether the systolic blood pressure is greater or less than 130 
mmHg and whether or not they are on antihypertensive medication.  
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